Innovation in the pharmaceutical industry: New estimates of R&D costs

Journal of Health Economics

Volumn 47, Issue , 2016, Pages 20-33

  DiMasi, Joseph A ^a   Grabowski, Henry G ^b   Hansen, Ronald W ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Discount rate; Innovation; Pharmaceutical industry; R D cost; Technical success rates

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

BIOTECHNOLOGY; DRUG DEVELOPMENT; INDUSTRIAL DEVELOPMENT; INDUSTRIAL TECHNOLOGY; INNOVATION; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT; TECHNOLOGICAL DEVELOPMENT;

ARTICLE; CAPITAL; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; ECONOMIC RECESSION; FINANCIAL DEFICIT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH EQUITY; HEALTH SURVEY; HUMAN; INCOME; NONHUMAN; ORGANIZATION; PUBLIC-PRIVATE PARTNERSHIP; PUBLISHING; RESEARCH AND DEVELOPMENT; SENSITIVITY ANALYSIS; TAX; VALIDATION PROCESS; COST; ECONOMICS; FINANCIAL MANAGEMENT; MEDICAL RESEARCH; UNITED STATES;

BIOMEDICAL RESEARCH; CAPITAL FINANCING; COSTS AND COST ANALYSIS; DRUG INDUSTRY; UNITED STATES;

EID: 84959128138     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2016.01.012     Document Type: Article

References (50)

1. Adams C.P., Brantner V.V. Estimating the cost of new drug development: is it really $802 million?. Health Affairs 2006, 25(March/April (2)):420-428.
2. Adams C.P., Brantner V.V. Spending on new drug development. Health Economics 2010, 19(2):130-141.
3. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It 2005, Random House, New York, NY.
4. Berndt E.R., Gottschalk A.H.B., Philipson T.J., Strobeck M.W. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nature Reviews Drug Discovery 2005, 4(7):545-554.
5. Berndt E.R., Nass D., Kleinrock M., Aitken M. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Affairs 2015, 34(2):245-252.
6. Burgess D.F., Zerbe R.O. The most appropriate discount rate. Journal of Benefit-Cost Analysis 2013, 4(3):391-400.
7. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 1991, 10(2):107-142.
8. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the U.S. pharmaceutical industry. PharmacoEconomics 1995, 7:152-169.
9. DiMasi J.A., Grabowski H.G., Vernon J. R&D costs, innovative output and firm size in the pharmaceutical industry. International Journal of the Economics of Business 1995, 2:201-219.
10. DiMasi J.A. New drug development in the United States from 1963 to 1999. Clinical Pharmacology & Therapeutics 2001, 69(5):286-296.
11. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003, 22(2):151-185.
12. DiMasi J.A., Hansen R.W., Grabowski H.G. Assessing Claims About the Cost of New Drug Development: A Critique of the Public Citizen and TB Alliance Reports 2004, November, http://csdd.tufts.edu/files/uploads/assessing_claims.pdf (accessed 16.07.14).
13. DiMasi J.A., Hansen R.W., Grabowski H.G. Reply: extraordinary claims require extraordinary evidence. Journal of Health Economics 2005, 24(5):1034-1044.
14. DiMasi J.A., Hansen R.W., Grabowski H.G. Setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. Journal of Health Economics 2005, 24(5):1049-1053.
15. DiMasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: is biotech different?. Managerial & Decision Economics 2007, 28(4-5):285-291.
16. DiMasi J.A., Feldman L., Seckler A., Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 2010, 87(3):272-277.
17. DiMasi J.A., Reichert J.M., Feldman L., Malins A. Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics 2013, 94(3):329-335.
18. DiMasi J.A., Kim J., Getz K.A. The impact of collaborative and risk-sharing innovation approaches on clinical and regulatory cycle times. Therapeutic Innovation and Regulatory Science 2014, 48(3):482-487.
19. DiMasi J.A. Regulation and economics of drug development. Presentation at the American Diabetes Association 75th Scientific Sessions 2015, http://professional.diabetes.org/presentations_details.aspx?session=4619 (accessed 27.11.15).
20. Divino V., Dekoven M., Weiying W., Kleinrock M., Harvey R.D., Wade R.L., Kaura S. The budget impact of orphan drugs in the US: a 2007-2013 MIDAS sales data analysis. Presentation at the 56th ASH Annual Meeting and Exposition 2014, http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Home%20Page%20Content/Real-World%20insights/IMS-Celgene_Orphan_Drugs_ASH_Presentation_Slides.pdf (accessed 25.05.15).
21. Food and Drug Administration Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008, December, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
22. Getz K.A., Wenger J., Campo R.A., Seguine E.S., Kaitin K.I. Assessing the impact of protocol design changes on clinical trial performance. American Journal of Therapeutics 2008, 15:450-457.
23. Getz K.A., Kaitin K.I. Why is the pharmaceutical industry struggling?. Re-Engineering Clinical Trials 2015, 3-15. Academic Press, London, UK. P. Schuber, B.M. Buckley (Eds.).
24. Gilbert J., Henske P., Singh A. Rebuilding big pharma's business model. In Vivo 2003, 21(10):1-10.
25. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press, New York, NY.
26. Goozner M. The 800 Million Dollar Pill: The Truth Behind the Cost of New Drugs 2004, University of California Press, Berkeley, CA.
27. Hall B.H. The financing of research and development. Oxford Review of Economic Policy 2002, 18(1):35-51.
28. Hansen R.W. The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. Issues in Pharmaceutical Economics 1979, 151-187. Lexington Books, Lexington, MA. R.I. Chien (Ed.).
29. Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology 2014, 32:40-51.
30. Ibbotson Associates Stocks, Bonds, Bills & Inflation: 2000, 2005, 2010 Yearbook 2000, 2005, 2010, Ibbotson Associates, Chicago, IL.
31. Lesko L.J. Introduction: Rare Diseases, Orphan Drugs 2011, March, Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM247635.pdf (accessed 29.05.15).
32. Light D., Warburton R. Extraordinary claims require extraordinary evidence. Journal of Health Economics 2005, 24(5):1030-1033.
33. Light D., Warburton R. Setting the record straight in the reply by DiMasi, Hansen and Grabowski. Journal of Health Economics 2005, 24(5):1045-1048.
34. Love J. Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines 2003, Consumer Project on Technology, Washington, DC.
35. Mestre-Ferrandiz J., Sussex J., Towse A. The R&D Cost of a New Medicine 2012, Office of Health Economics, London, UK.
36. Moore M.A., Boardman A.E., Vining A.R. More appropriate discounting: the rate of social time preference and the value of the social discount rate. Journal of Benefit-Cost Analysis 2013, 4(1):1-16.
37. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 2009, 8(12):959-968.
38. Myers S.C., Howe C.D. A Life-Cycle Financial Model of Pharmaceutical R&D, Working Paper, Program on the Pharmaceutical Industry 1997, Massachusetts Institute of Technology, Cambridge, MA.
39. O'Hagan P., Farkas C. Bringing Pharma R&D Back to Health 2009, Bain & Company, Boston, MA.
40. Pammolli F., Magazzini L., Ricaboni M. The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 2011, 10(6):428-438.
41. PAREXEL PAREXEL Pharamceutical R&D Statistical Sourcebook, Waltham, MA 2005, M.P. Mathieu (Ed.).
42. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 2010, 9(3):203-214.
43. Scherer F.M., Harhoff D. Technology policy for a world of skewed-distributed outcomes. Research Policy 2000, 29(4-5):559-566.
44. Stergiopoulas S., Getz K.A. Mapping and characterizing the development pathway from non-clinical through early clinical development. Pharmaceutical Medicine 2012, 26(5):297-307.
45. Young B., Surrusco M. Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card 2001, July, Public Citizen, Congress Watch, Washington, DC.
46. US Congressional Budget Office How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry 1998, July, US Government Printing Office, Washington, DC.
47. US Congressional Budget Office Research and Development in the Pharmaceutical Industry 2006, October, US Government Printing Office, Washington, DC.
48. U.S.Congress, Joint Committee on Taxation Estimates of Federal Tax Expenditures for Fiscal Years 2012-2017 2013, 30-44. U.S. Government Printing Office, Washington, DC, Table 1.
49. Vernon J.A. Pharmaceutical R&D investments and cash flows. Journal of Pharmaceutical Finance, Economics & Policy 2004, 13(4):35-51.
50. Viereck C., Boudes P. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary Clinical Trials 2011, 32(3):324-332.